Alkermes to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Declining Stock and Solid Fundamentals: Is The Market Wrong About Alkermes Plc (NASDAQ:ALKS)?
Mizuho Securities Maintains Alkermes(ALKS.US) With Buy Rating, Announces Target Price $40
Alkermes Prepares for New Flexibility Post Credit Termination
Analysts Conflicted on These Healthcare Names: Talkspace (TALK), Centene (CNC) and Alkermes (ALKS)
Analysts Offer Insights on Healthcare Companies: Viridian Therapeutics (VRDN), DocGo (DCGO) and Alkermes (ALKS)